Last reviewed · How we verify
NCT06686082
A Real-World Study of Biologic Therapy for Subclinical Psoriatic Arthritis
trial testing Biologics in Subclinical Psoriatic Arthritis in 150 participants. Enrolling by invitation.
30 November 2024
Quick facts
| Lead sponsor | Chao Ji |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 1 November 2023 |
| Primary completion | 30 November 2024 |
| Estimated completion | 25 March 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Biologics
Conditions studied
- Subclinical Psoriatic Arthritis — all drugs for Subclinical Psoriatic Arthritis →
Sponsor
Chao Ji — full company profile →
Who can join
18 and older, any sex, with Subclinical Psoriatic Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Psoriatic arthritis (PsA) is one of the most common comorbidities in patients with psoriasis (PsO). Current research suggests that the progression from PsO to PsA can be divided into five stages of the disease: PsO, preclinical PsA, subclinical PsA, prodromal PsA, and clinical PsA. Subclinical PsA refers to psoriasis participants who do not exhibit any clinical symptoms of arthritis but show evidence of synovio-enthesitis on ultrasound (US). However, there is currently no definitive biomarker that can accurately predict the progression from PsO to PsA. Synovitis and enthesitis are considered important features of PsA. Musculoskeletal ultrasound, using B-mode ultrasound and power Doppler (PD), can visualize synovitis and enthesitis, allowing for the early detection of subclinical PsA, as confirmed by multiple studies. Biologics are currently widely used in the treatment of PsA, with current treatment interventions primarily focusing on patients already diagnosed with PsA. In this study, we conducted a rigorous screening process to identify potential subclinical PsA patients among those with moderate to severe psoriasis. We treated these subclinical PsA patients with biologics and used musculoskeletal ultrasound as a method of efficacy assessment to observe the improvement of synovitis and enthesitis in subclinical PsA patients after 12 weeks of treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06686082
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biologics
Trials testing the same drug.
- NCT05542459 — Multi-omics to Predict Responses to Biologics in IBD · unknown
Other Chao Ji trials
Trials by the same sponsor.
- NCT06663943 — A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313. · Phase 1, PHASE2 · not yet recruiting
- NCT06654817 — Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Tr · completed
- NCT06561256 — JAK Inhibitors' Efficacy in Bullous Pemphigoid · completed
- NCT06391996 — Biologic Therapy for Generalized Pustular Psoriasis · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06686082 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chao Ji
- Last refreshed: 25 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06686082.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing